EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine

Raquel Matavele Chissumba iD, Gaurav Kwatra, Patrícia Ramgi iD, Maria Enosse, Adérito Sigaúque, Celso Khosa iD, Edna Viegas, Odete Bule iD, José Langa, Nisha Dhar, Christian Mukendi, Denise Langa und 8 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Raquel Matavele Chissumba und 19 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Nacional de Saúde, Marracuene, Mozambique. Hauptthemen laut MEDLINE: Antibodies, Viral, COVID-19 Vaccines, SARS-CoV-2, COVID-19. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

More than half of the BBIBP-CorV vaccines, outside of Pacific Asia, were distributed in Africa. Nevertheless, there are limited data on the immunogenicity of BBIBP-CorV from Africa. We compared the antibody response, after 1 and 2 doses of the BBIBP-CorV vaccine, in individuals seropositive or seronegative to severe acute respiratory syndrome coronavirus 2 prior to vaccination.

Methods

From March to May 2021, blood samples were obtained at first and second doses of the BBIBP-CorV, and 2 weeks later. Antibody titers against the full-length spike, receptor binding domain and nucleocapsid protein (anti-NC) of severe acute respiratory syndrome coronavirus 2 were measured. Pseudovirus neutralization assays and antibody-dependent cellular cytotoxicity (ADCC) against the D614G, BA.2, and BA.4 variants were also evaluated.

Results

At the second dose, the immunoglobulin G titers for full-length spike and anti-nucleocapsid protein, the ADCC against BA-2, and the neutralizing activity against the D614G and BA.2 were higher in individuals seropositive to any of the epitopes at the first dose (n = 26) compared to the levels observed 2 weeks later in the seronegative group (n = 25). We did not observe an increase on magnitude of binding antibodies, ADCC, and neutralizing activities, in those seropositive, after the second homologous dose of the BBIBP-CorV vaccine.

Conclusions

We suggest that 1 dose of the BBIBP-CorV vaccine in seropositive individuals induced better antibodies response including against variant of concerns compared to that observed after 2 doses in seronegative individuals. A further homologous dose of the BBIBP-CorV vaccine, in those who are seropositive, does not improve the antibody response observed after the first dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralCOVID-19 VaccinesSARS-CoV-2COVID-19HumansAntibodies, NeutralizingAdultMaleFemaleMozambiqueSpike Glycoprotein, CoronavirusMiddle AgedYoung AdultImmunogenicity, VaccineCohort StudiesVaccinationAntibody-Dependent Cell CytotoxicityAdolescentVaccines, Inactivated

Stichwörter der Autor:innen

BBIBP-CorVCOVID-19 vaccineantibodieshybrid immunityinactivated vaccine

Substanzen

Antibodies, ViralCOVID-19 VaccinesAntibodies, NeutralizingSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2BIBP COVID-19 vaccineVaccines, Inactivated

Autor:innen und Institutionen

  • Instituto Nacional de Saúde, Marracuene, Mozambique.
  • Centro de Investigação e Desenvolvimento em Etnobotânica, Namaacha, Mozambique.
  • Department of Clinical Microbiology, Christian Medical College, Vellore, India.
  • South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio, USA.
  • Department of Physiological Science, Clinical Pharmacology, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.

ORCID-Profile: Raquel Matavele Chissumba, Patrícia Ramgi, Celso Khosa, Odete Bule, Simone Richardson, Ilesh V Jani

Förderung

  • Bill and Melinda Gates Foundation

Zitieren

APA

Chissumba, R. M., Kwatra, G., Ramgi, P., Enosse, M., Sigaúque, A., Khosa, C., Viegas, E., Bule, O., Langa, J., Dhar, N., Mukendi, C., Langa, D., Sevene, E., Hermanus, T., Manamela, N., Richardson, S., Moore, P., Madhi, S., Jani, I. V., & SIVCOV study group (2025). Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf095

Vancouver

Chissumba RM, Kwatra G, Ramgi P, Enosse M, Sigaúque A, Khosa C, et al. Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf095

BibTeX
@article{Chissumba2025,
  author = {Chissumba, Raquel Matavele and Kwatra, Gaurav and Ramgi, Patrícia and Enosse, Maria and Sigaúque, Adérito and Khosa, Celso and Viegas, Edna and Bule, Odete and Langa, José and Dhar, Nisha and Mukendi, Christian and Langa, Denise and Sevene, Esperança and Hermanus, Tandile and Manamela, Nelia and Richardson, Simone and Moore, Penny and Madhi, Shabir and Jani, Ilesh V and SIVCOV study group, SIVCOV study group},
  title = {Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf095}
}
Kostenlos starten →